A METHOD FOR USE IN DETERMINATION OF APOPTOTIC SPERMS

Abstract

Disclosed is a method for live detection of apoptotic sperms contained in a sperm sample under in vitro conditions.

Claims

1. A method for use in in vitro detection of apoptotic sperms in a sperm sample wherein said method comprises the steps of: a. Preparation of latex beads coated with a protein having phosphatidylserine affinity; b. Treatment of prepared latex bead with prepared sperm sample; c. Evaluation of sperm sample using light microscope; and d. Identification of sperms that are attached to latex beads as apoptotic sperms.

2. A method according to claim 1, wherein the step a comprises the steps of: a1) pretreating the latex beads; and a2) coating the pretreated latex beads with a protein having affinity for phosphatidylserine.

3. A method according to claim 2, wherein step a1) comprises the steps of diluting the latex bead solution in a suitable buffer, centrifugation of the resulting mixture, discarding the supernatant then re-diluting the remaining particles with buffer and centrifugation of the particles and discarding the supernatant and then suspending the remaining particles with a suitable buffer, preferably with a buffer so as to form a 2% solution.

4. A method according to claim 3, wherein the latex bead solution is 40 mg/ml IDC UltraClean Amidine Latex bead solution.

5. A method according to claim 3, wherein the suitable buffer is 0.025M, pH 6 MES (2-(N-morpholinoethanesulfonic acid) buffer.

6. A method according to claim 2, wherein step a2) comprises the steps of addition of 50 mg/ml of ED AC (1-Ethyl-3-(3-dimethylaminopropyl carbodiimide) solution in a suitable buffer to the latex bead solution obtained in step a1), addition of a protein that has phosphatidylserine affinity in a suitable buffer to said solution, incubating the mixture at room temperature for 2-5 hours, then centrifuging the mixture to remove free protein from the latex beads that bind to the protein that has phosphatidylserine affinity, after discarding the supernatant, the particles are diluted with PBS ((phosphate buffered saline solution/buffer) 0.1M, pH 7.2) followed by centrifuge, optionally repeating this process 3-4 times, after discarding the supernatant suspending the precipitate (pellets) in the storage buffer at a concentration of 1%.

7. A method according to claim 6, wherein the suitable buffer is 0.025M, pH 6 MES (2-(N-morpholino) ethanesulfonic acid) buffer.

8. A method according to claim 6, wherein the storage buffer is 0.1 M PBS having a pH of 7.2 comprising 0.1% glycine, 0.1% sodium azide.

9. A method according to claim 1, further comprising the step of identifying the sperms defined as apoptotic in the sperm sample.

10. A method according to claim 1 wherein the protein having phosphatidylserine affinity is selected from a group consisting of: annexins, protein kinase C (PKC), synaptotagmin, phospholipase C (PLC), rabfilin, DOC1, DOC2, MARCKS, Vinculin, Lactadherin, Gas-6, Raf-1, DGK, SK1, NO synthase, FGF.

11. A method according to claim 10 wherein the Annexins are selected from a group comprising 12 members determined in humans.

12. A method according to claim 11 wherein the Annexins are selected from a group consisting of: Annexin type I, Annexin type II, Annexin type III, Annexin type IV, Annexin type V (or Annexin A5), Annexin type VI, Annexin giardin, Annexin type VII, Annexin type VIII, Annexin type X, Annexin type XI, Annexin type XIII, Annexin type XIV, Annexin type XXXI.

13. A method according to claim 12 wherein the Annexin is Annexin V.

14. A method according to claim 1, wherein the protein having an affinity for phosphatidylserine is used in conjugation with a fluorescent or an enzymatic tag or biotin.

15. A method according to claim 1, for use in quantifying apoptotic sperm in a sperm sample under in vitro conditions.

16. A method according to claim 1, for use in separation of healthy sperms and apoptotic sperms in a sperm sample under in vitro conditions.

17. A method according to claim 1, for use in the detection of apoptotic sperms in a sperm sample under in vitro conditions.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0012] The present invention is directed to the use of a light microscopic technique that allows for the in vitro labeling of apoptotic sperm from a sperm sample, thereby allowing the identification of non-apoptosis-detected sperm.

[0013] The method according to the invention is distinguished from the methods known in the art because it allows the analysis of live sperms, allows the selection of non-apoptotic sperms for microinjection (ICSI) method, allows to work under sterile conditions, and that it dose not require use of an extra equipment and training.

[0014] In one aspect, the invention relates to a method for the detection of apoptotic sperms in an in vitro sperm sample, wherein said method comprises the steps of; [0015] a. Preparation of latex beads coated with a protein having phosphatidylserine affinity [0016] b. Treatment of prepared latex bead with prepared sperm sample [0017] c. Evaluation of sperm sample using light microscope [0018] d. Identification of sperms that are attached to latex beads as apoptotic sperms. [0019] e. Optionally, selecting the healthy sperms that did not adhere to the latex bead and using them.

[0020] In a preferred embodiment of the invention, step a) comprises the steps of; a1) pre-treating the latex beads; and a2) coating the pre-treated latex beads with a protein having affinity for phosphatidylserine.

[0021] In a preferred embodiment of the invention, step a1) comprises the steps of diluting the latex bead solution, preferably a solution of 40 mg/ml IDC UltraClean Amidine latex bead solution, in a suitable buffer, preferably with 0.025M, pH 6 MES buffer (2-(N-morpholino) ethanesulfonic acid), discarding the supernatant then re-diluting the remaining particles with buffer, preferably with 0.025M, pH 6 MES buffer (2-(N-morpholino) ethanesulfonic acid), centrifugation of the particles and discarding the supernatant and then suspending the remaining particles with a suitable buffer, preferably with 0.025M, pH 6 MES buffer (2-(N-morpholino) ethanesulfonic acid), so as to form a 2% solution.

[0022] In a preferred embodiment of the invention, step a2) comprises the steps of addition of 50 mg/ml of EDAC (1-Ethyl-3-(3-dimethylaminopropyl carbodiimide) solution in a suitable buffer, preferably 0.025M, pH 6 MES (2-(N-morpholino)ethane sulfonic acid) buffer (e.g. 100 mg EDAC in 2 ml MES), to the latex bead solution obtained in step a1), addition of a protein that has phosphatidylserine affinity in a suitable buffer, preferably in 0.025M, pH 6 MES (2-(N-morpholino)ethane sulfonic acid), to said solution, incubating the mixture at room temperature for 2-5 hours, then centrifuging the mixture to remove free protein from the latex beads that bind to the protein that has phosphatidylserine affinity, after discarding the supernatant, the particles are diluted with PBS ((phosphate buffered saline solution/buffer) 0.1M, pH 7.2) followed by centrifuge, optionally repeating this process 3-4 times, after discarding the supernatant suspending the precipitate (pellets) in the storage buffer (0.1 M PBS, 0.1% glycine, 0.1% sodium azide, pH 7.2) at a concentration of 1%.

[0023] As used herein, the term “protein with phosphatidylserine affinity” refers to proteins with a double-layered lipid structure and susceptible to binding to phosphatidylserine on the outer surface of apoptotic cells. Proteins with phosphatidylserine affinity are selected from a group comprising annexins, protein kinase C (PKC), synaptotagmin, phospholipase C (PLC), rabfilin, DOC1, DOC2, MARCKS, Vinculin, Lactadherin, Gas-6, Raf-1, DGK, SK1, NO synthase, FGF.

[0024] Annexins mentioned herein are selected from a group comprising Annexin type I, Annexin type II, Annexin type III, Annexin type IV, Annexin type V (or Annexin A5), Annexin type VI, Annexin giardin, Annexin type VII, Annexin type VIII, Annexin type X, Annexin type XI, Annexin type XIII, Annexin type XIV, Annexin type XXXI

[0025] In a preferred embodiment of the invention, Annexin that have phosphaditylserine affinity is particularly preferably Annexin V (Annexin A5).

[0026] In one embodiment of the invention, proteins with affinity for phosphatidylserine may be used in conjugation with a fluorescent or an enzymatic tag or biotin.

[0027] During the application of the process according to the invention, solutions that would help realizing the process can be for example prepared with water or any other suitable buffer solution that are readily accessible to the person skilled in the art.

[0028] Another aspect of the invention is the use of a method according to the invention for determining the amount of apoptotic sperms in a sperm sample.

[0029] Another aspect of the invention is the use of the method according to the invention for separating healthy sperm from apoptotic sperm in a sperm sample.

[0030] In a preferred embodiment of the invention, the sperm determined to be apoptotic sperm by the method according to the invention can be selected and separated from healthy sperm under microscope.

[0031] The invention will now be described by way of example only with reference to the following examples, which are intended to be exemplary only and are not to be construed in any way as limiting the scope of the invention.

EXAMPLES

Example 1

Production of Annexin V Coated Latex Beads

[0032] A) Pre-Treatment of Latex Beads

[0033] First, 2.5 ml (40 mg/ml) of the IDC UltraClean Amidine Latex bead solution is diluted in 10 ml 0.025M, pH 6 MES buffer (2-(N-morpholino) ethanesulfonic acid). The mixture is then centrifuged to precipitate the particles. The supernatant is discarded and 10 ml of MES buffer is added again to the mixture, centrifuged again and the supernatant is separated from the particles and discarded. 5 ml MES buffer was added to the obtained latex beads to suspend the beads to obtain Latex beads ready for Annexin V coating (as a 2% solution).

[0034] B) Coating of Pre-Treated Latex Beads with a Protein Having Affinity for Phosphatidylserine

[0035] To the prepared 2% latex bead solution, a solution of EDAC (1-Ethyl-3-(3-dimethylaminopropyl carbodiimide) with 50 mg/ml in MES buffer (eg 100 mg EDAC in 2 ml MES) is added. Annexin V antibody is then added to the solution in 5 ml MES buffer (containing 5 mg antibody). The mixture is incubated at room temperature with shaking for 3-4 hours. The mixture is then centrifuged to separate the free Annexin V with latex beads attached to Annexin V. The supernatant is discarded. The precipitate (pellet) is suspended in 10 ml of PBS (phosphate buffered saline solution/buffer, 0.1M, pH 7.2). The particles are centrifuged again to precipitate. This washing step is repeated 3-4 more times using PBS. Finally, the pellet is suspended in 10 ml of storage buffer (0.1 M PBS, 0.1% glycine, 0.1% sodium azide, pH 7.2) and brought to a concentration of 1%.

Example 2

Detection of Apoptotic Sperm Cells Using Annexin V-bound Latex Beads

[0036] Annexin V coated latex bead solution and the liquefied semen sample are mixed in vitro on a slide in a 1:1 ratio and kept for 1-5 minutes, preferably 2 minutes. The sperm are then evaluated under a light microscope, preferably using a 40× objective. Since the apoptotic sperm cells in the semen sample are bound to Annex in V, these sperm will appear to be surrounded by latex beads and will be classified as apoptotic sperm cells. Sperm cells not surrounded by latex beads will be classified as healthy sperm without apoptosis. In this way, healthy sperm not surrounded by beads can be selected for microinjection.

[0037] Around these basic concepts, it is possible to develop a wide variety of applications relating to the subject matter of the invention, the invention being not limited to the examples described herein, but essentially as set forth in the claims.

[0038] It is evident that a person skilled in the art can demonstrate the novelty disclosed in the invention using similar embodiments and/or may apply this embodiment to other fields of similar purpose as are used in the art. It is therefore evident that such embodiments will lack the criterion of innovation and in particular overcome the prior art.